


## PHARMACEUTICAL 2018

## Aptevo Therapeutics Inc. Rank 31 of 349







## PHARMACEUTICAL 2018



## Aptevo Therapeutics Inc. Rank 31 of 349



The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 331% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 156%, being 433% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	95,084
Cost of Goods Sold	0
Intangible Assets	6,080
Liabilities, Current	18,510
Liabilities, Non-Current	16,462
Other Assets	10,000
Other Compr. Net Income	-72
Other Expenses	-18,291
Other Liabilities	0
Other Net Income	37,621
Property and Equipment	5,843
Research and Development	29,021
Revenues	14,658
Selling, General and Administrative Expense	34,576

Output Variable	Value in 1000 USD
Assets	117,007
Liabilities	34,972
Expenses	45,306
Stockholders Equity	82,035
Net Income	6,973
Comprehensive Net Income	6,937
Economic Capital Ratio	156%